Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2019 Financial Results

Author's Avatar
May 09, 2019
Article's Main Image

- Etrasimod ELEVATE UC Phase 3 Program expected to initiate mid-year targeting significant unmet need in ulcerative colitis

- Multiple first- or best-in-class therapeutics, strong leadership team and liquidity position of approximately $1.3 billion

PR Newswire